GRAIL, Inc. Research and Development Expense
GRAIL, Inc. (GRAL) reported Research and Development Expense of $47.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- GRAIL, Inc. research and development expense for the quarter ending 2026-06-30 was $47.43M, a 1.72% increase year-over-year.
- GRAIL, Inc. research and development expense for the quarter ending 2026-03-31 was $48.02M, a 10.45% decline year-over-year.
- GRAIL, Inc. research and development expense for the quarter ending 2025-12-31 was $46.90M, a 2.96% decline year-over-year.
- GRAIL, Inc. research and development expense for the quarter ending 2025-09-30 was $48.65M, a 37.82% decline year-over-year.
- GRAIL, Inc. research and development expense for fiscal 2025 was $195.79M, a 39.27% decline from fiscal 2024.
- GRAIL, Inc. research and development expense for fiscal 2024 was $322.38M, a 4.83% decline from fiscal 2023.
- GRAIL, Inc. research and development expense for fiscal 2023 was $338.75M, a 2.78% increase from fiscal 2023.
- GRAIL, Inc. research and development expense for fiscal 2023 was $329.58M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.43M 10-Q · filed 2026-08-06 | $95.45M 10-Q · filed 2026-08-06 | $142.35M derived: sum of 3 quarters · filed 2026-08-06 | $190.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $48.02M 10-Q · filed 2026-05-07 | $94.92M derived: sum of 2 quarters · filed 2026-05-07 | $143.56M derived: sum of 3 quarters · filed 2026-05-07 | $190.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $46.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $95.54M derived: sum of 2 quarters · filed 2026-03-12 | $142.17M derived: sum of 3 quarters · filed 2026-08-06 | $195.79M 10-K · filed 2026-03-12 |
| 2025-09-30 | $48.65M 10-Q · filed 2025-11-13 | $95.27M derived: sum of 2 quarters · filed 2026-08-06 | $148.90M 10-Q · filed 2025-11-13 | $197.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $46.63M 10-Q · filed 2026-08-06 | $100.25M 10-Q · filed 2026-08-06 | $148.58M derived: sum of 3 quarters · filed 2026-08-06 | $226.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $53.63M 10-Q · filed 2026-05-07 | $101.95M derived: sum of 2 quarters · filed 2026-05-07 | $180.18M derived: sum of 3 quarters · filed 2026-05-07 | $274.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $48.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $126.56M derived: sum of 2 quarters · filed 2026-03-12 | $220.75M derived: sum of 3 quarters · filed 2026-03-12 | $322.38M 10-K · filed 2026-03-12 |
| 2024-09-30 | $78.23M 10-Q · filed 2025-11-13 | $172.43M derived: sum of 2 quarters · filed 2025-11-13 | $274.05M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $94.20M 10-Q · filed 2025-08-13 | $195.82M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $101.63M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $338.75M 10-K · filed 2025-03-05 | |||
| 2023-01-01 | $329.58M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |